May 20, 2019
Another session in “dreary” land; portfolios need a “fix” of upside while suffering a lack of “umpf”
Three biotechs (Peloton Therapeutics, Ideaya Biosciences and U.K. based Bicycle Therapeutics) are going IPO this week (read more)
Pre-open indications: 2 BUYs and 3 SELLs
Unique insights from what's likely to remain a volatile climate; RMi outlines preludes and aftermaths defining the daily dose of factors, investment thesis and objectivity!
May 20, 2019
Volatility, algorithms, sustainability … how are enrollments going as to population and is data from on-going trials being interpreted to render measurable and definitive outcomes?
Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019?
Why spend time finding sector news and analytics … it’s all right here!
May 17, 2019
It is not unusual for stocks to weaken at the end of a week; the sector needs a fix of market moving news or we will be stuck with potential “black swans”
Pre-open indications: 4 HITs and 2 MISS (1 by a penny)
The sector is what it is, until it isn’t and even then it doesn’t seem to be … when you point one finger, there are three fingers pointing back at you!
May 20, 2019
Volatility, algorithms, sustainability … how are enrollments going as to population and is data from on-going trials being interpreted to render measurable and definitive outcomes? Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019? Why spend time finding sector news and analytics … it’s all right here!
May 19, 2019
A scorecard of earnings of 45 covered companies 41 so far: 2 acquired (AST, OSIR) 1 on acquisition hold - ONCE) and 1 set to be reversed (HSGX) ... The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
March 31, 2019
A scorecard of (AKA) earnings of 45 covered companies 44 out of 45 ... The current LPS (loss per share) or net income, cash positions i.e. "runways" - it's a reflection of this universe's investing "status"
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
